Aptevo Therapeutics
APVO
10 hedge funds and large institutions have $717K invested in Aptevo Therapeutics in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
1,464% more capital invested
Capital invested by funds: $45.9K → $717K (+$671K)
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
150% more funds holding
Funds holding: 4 → 10 (+6)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.81% more ownership
Funds ownership: 0.03% → 0.83% (+0.81%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$669K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
+$293K |
| 3 |
VF
Virtu Financial
New York
|
+$85.4K |
| 4 |
Focus Partners Wealth
Boston,
Massachusetts
|
+$22.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$12.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Birchview Capital
Burlington,
Vermont
|
-$30.5K |
| 2 |
SS
SBI Securities
Tokyo,
Japan
|
-$40 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Point72 Asset Management
Stamford,
Connecticut
| $435K | +$669K | +16,664 | New |
|
|
DS
2
DRW Securities
Chicago,
Illinois
| $191K | +$293K | +7,304 | New |
|
|
VF
3
Virtu Financial
New York
| $56K | +$85.4K | +2,127 | New |
|
|
4
Focus Partners Wealth
Boston,
Massachusetts
| $14.5K | +$22.3K | +556 | New |
|
5
Osaic Holdings
Scottsdale,
Arizona
| $9.76K | +$7.23K | +180 | +99% |
|
|
6
UBS Group
Zurich,
Switzerland
| $8.23K | +$12.7K | +315 | New |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $2.1K | +$562 | +14 | +21% |
|
|
SS
8
SBI Securities
Tokyo,
Japan
| $827 | -$40 | -1 | -3% |
|
9
Citigroup
New York
| $107 | +$161 | +4 | New |
|
10
Bank of America
Charlotte,
North Carolina
| $39 | +$80 | +2 | New |
|
11
BlackRock
New York
| $1 | – | – | – |
|
|
DB
12
Danske Bank
Copenhagen K,
Denmark
| $1 | – | – | – |
|
|
BC
13
Birchview Capital
Burlington,
Vermont
| – | -$30.5K | -556 | Closed |
|
APVO Hedge Fund Activity: Q3 2025 in Review
10 of the 7,624 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q3 2025, worth a combined $717K — up 1,464% from $45.9K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new APVO positions and 1 closed out — a net gain of 6 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $669K. The largest seller was Birchview Capital, exiting entirely with an estimated $30.5K sold.
- 10 institutional investors held Aptevo Therapeutics (APVO) as of Q3 2025, up from 4 in Q2 2025.
- Funds reported $717K of Aptevo Therapeutics stock for Q3 2025, up 1,464% quarter-over-quarter.
- 7 funds opened new Aptevo Therapeutics positions in Q3 2025 and 1 closed out, a net change of +6 holders.
- The largest Aptevo Therapeutics buyer in Q3 2025 was Point72 Asset Management, an estimated $669K added.
- The largest Aptevo Therapeutics seller in Q3 2025 was Birchview Capital, an estimated $30.5K sold.
Based on aggregated 13F filings for Q3 2025.